{"id":10164,"date":"2021-06-03T14:59:54","date_gmt":"2021-06-03T21:59:54","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=10164"},"modified":"2021-06-04T15:15:38","modified_gmt":"2021-06-04T22:15:38","slug":"covid-19-literature-situation-report-june-3-2021","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/06\/03\/covid-19-literature-situation-report-june-3-2021\/","title":{"rendered":"COVID-19 Literature Situation Report June 3, 2021"},"content":{"rendered":"<p>The scientific literature on COVID-19 is rapidly evolving and these articles were selected for review based on their relevance to Washington State decision making around COVID-19 response efforts. Included in these Lit Reps are some manuscripts that have been made available online as pre-prints but have not yet undergone peer review. Please be aware of this when reviewing articles included in the Lit Reps.<\/p>\n<p><em>Today&#8217;s summary is based on a review of 1021 articles (996 published, 25 in preprint)<\/em><\/p>\n<p><strong><a href=\"https:\/\/depts.washington.edu\/pandemicalliance\/wordpress\/wp-content\/uploads\/2021\/06\/LitRep_20210603.pdf\">View the PDF version here.<\/a><\/strong><\/p>\n<h2>Key Takeaways<\/h2>\n<ul>\n<li><b>Preventive treatment with the monoclonal antibody bamlanivimab reduced the risk of COVID-19 among residents and staff of skilled nursing facilities who were negative for SARS-CoV-2 infection and seronegative at baseline in a randomized trial (8.5% vs 15.2%, OR=0.43 95% CI 0.28-0.68). <\/b><a href=\"https:\/\/doi.org\/10.1001\/jama.2021.8828\"><span style=\"font-weight: 400\">More<\/span><\/a><\/li>\n<\/ul>\n<ul>\n<li style=\"font-weight: 400\"><b>Effectiveness of the Pfizer-BioNTech vaccine &gt;7 days after the second dose among high-risk groups ranged between 53-86% in preventing SARS-CoV-2 infection, \u226575% in preventing COVID-19 hospitalizations, and \u226589% in preventing COVID-19 deaths, based on findings from a nationwide cohort study of high-risk groups in Denmark. Vaccine effectiveness against all COVID-19 related outcomes were lowest among long-term care facility residents. <\/b><a href=\"https:\/\/doi.org\/10.1101\/2021.05.27.21257583\"><span style=\"font-weight: 400\">More<\/span><\/a><\/li>\n<\/ul>\n<div id=\"uw-accordion-shortcode\">\n<h3>Article Summaries<\/h3>\n<div class=\"js-accordion\" data-accordion-prefix-classes=\"uw-accordion-shortcode\">\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400\">Transmission<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-10166\" class=\"su-post\">\n<h5 class=\"su-post-title\">SARS-CoV-2 Infections and Viral Isolations among Serially Tested Cats and Dogs in Households with Infected Owners in Texas, USA<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">In a longitudinal study of 76 dogs and cats living with at least one SARS-CoV-2 infected human in Texas, 4 pets were PCR-positive for SARS-CoV-2, while 14 pets had detectable anti-SARS-CoV-2 neutralizing antibodies (including 2 of the 4 PCR-positive pets). Re-sampling showed persistent PCR positivity up to 25 days and sequencing of PCR samples showed viral genomes belonging to clades predominantly observed in human samples in Texas during the same period. Neutralizing activity among pets with detectable antibodies was relatively stable over 2-3 months of follow-up. 82% of infected pets were asymptomatic.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Hamer et al.\u00a0(May 19, 2021). SARS-CoV-2 Infections and Viral Isolations among Serially Tested Cats and Dogs in Households with Infected Owners in Texas, USA. Viruses. <\/span><\/i><a href=\"https:\/\/doi.org\/10.3390\/v13050938\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.3390\/v13050938<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400\">Geographic Spread<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-10168\" class=\"su-post\">\n<h5 class=\"su-post-title\">Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">A forecasting model incorporating North American prevalence of SARS-CoV-2 variants of concern from the genome database GISAID suggests that the B.1.1.7 variant could become dominant (&gt;60% of sequenced strains) by summer 2021 but would sharply decrease in frequency when 75% of the population is immune through vaccination or natural infection due to its high binding affinity to the neutralizing antibody CV30 (~90%). Though the B.1.351, B.1.617, and P.1 variants remain in low frequencies, they may each consist of up to 5% of strains even after high vaccination coverage due to their lower binding affinity to neutralizing antibodies (~70%).<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Quinonez et al.\u00a0(May 17, 2021). Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America. Viruses. <\/span><\/i><a href=\"https:\/\/doi.org\/10.3390\/v13050930\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.3390\/v13050930<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400\">Testing and Treatment<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-10172\" class=\"su-post\">\n<h5 class=\"su-post-title\">Performance of Self-Collected Saliva Testing Compared with Nasopharyngeal Swab Testing for the Detection of SARS-CoV-2<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">There was high correlation in the SARS-CoV-2 viral load measurements from paired self-collected pure saliva (SCPS) and nasopharyngeal swabs (NPS) from asymptomatic and mildly symptomatic patients with confirmed COVID-19 (r=0.72; n=31). SCPS performance was more similar to NPS among samples obtained from symptomatic adults, with 74% of samples in agreement.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Carrouel et al.\u00a0(May 12, 2021). Performance of Self-Collected Saliva Testing Compared with Nasopharyngeal Swab Testing for the Detection of SARS-CoV-2. Viruses. <\/span><\/i><a href=\"https:\/\/doi.org\/10.3390\/v13050895\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.3390\/v13050895<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10170\" class=\"su-post\">\n<h5 class=\"su-post-title\">Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Preventive treatment with the monoclonal antibody bamlanivimab reduced the risk of COVID-19 among residents and staff of skilled nursing facilities (n=966) who were negative for SARS-CoV-2 infection and seronegative at baseline in a randomized trial (8.5% vs 15.2%, OR=0.43 95% CI 0.28-0.68). All 5 deaths occurred in residents randomized to receive placebo. Participants were enrolled from 74 skilled nursing and assisted living facilities in the US and received the treatment (bamlanivimab or a placebo infusion) within 7 days of a confirmed SARS-CoV-2 case at their facility. They were followed for 24 weeks with 8 additional tests for SARS-CoV-2 infection by RT-PCR.\u00a0 Adverse events were balanced between the bamlanivimab and placebo groups.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Cohen et al. (June 3, 2021). Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities. JAMA. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1001\/jama.2021.8828\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1001\/jama.2021.8828<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\">Vaccines and Immunity<\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-10182\" class=\"su-post\">\n<h5 class=\"su-post-title\">Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Mild perimyocariditis following vaccination with the Pfizer-BioNTech vaccine was reported in 7 adolescent males aged 16-18 years across 3 pediatric medical centers in Israel. Patients presented with chest pain 1-3 days following vaccination, with symptoms beginning following the second dose in 6 of the 7 patients. All cases were mild, and none required cardiovascular or respiratory support. The authors note that the incidence of perimyocarditis during the vaccination period was elevated compared to previous years.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Snapiri et al.\u00a0(June 2, 2021). Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. The Pediatric Infectious Disease Journal. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1097\/INF.0000000000003235\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1097\/INF.0000000000003235<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10180\" class=\"su-post\">\n<h5 class=\"su-post-title\">Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">In a systematic review and meta-analysis of 25 randomized trials assessing safety and efficacy of COVID-19 vaccines, mRNA-based (e.g., Pfizer-BioNTech and Moderna) and adenovirus-vectored (e.g., Oxford-AstraZeneca, Johnson &amp; Johnson, Sputnik V) vaccines had the highest efficacy in phase 2\/3 trials (94.6% and 80.2%, respectively). The mRNA-based vaccines had the highest level of side effects reported, except for diarrhea and joint pain (arthralgia). All vaccines stimulated robust immune responses. Among 58,889 participants who received a COVID-19 vaccine and 46,638 controls who received a placebo included in the analysis, few extreme adverse effects were observed.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Pormohammad et al.\u00a0(May 6, 2021). Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines. <\/span><\/i><a href=\"https:\/\/doi.org\/10.3390\/vaccines9050467\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.3390\/vaccines9050467<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10178\" class=\"su-post\">\n<h5 class=\"su-post-title\">Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The Pfizer-BioNTech vaccine elicited worse local and systemic reactions among individuals with a history of allergy in an online survey of vaccinated medical professionals in Poland (n=1,808). However, no severe allergic reactions were reported. Local redness (17% vs 11%), pain (86% vs 80%), and swelling (19% vs 13%) after the first dose and vomiting (3% vs 1%) and joint pain (32% vs 26%) after the second dose were more frequent in allergic individuals. Other common symptoms such as fever and fatigue were not significantly different between the two groups.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Nittner-Marszalska et al.\u00a0(May 25, 2021). Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals. Vaccines. <\/span><\/i><a href=\"https:\/\/doi.org\/10.3390\/vaccines9060553\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.3390\/vaccines9060553<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10176\" class=\"su-post\">\n<h5 class=\"su-post-title\">Vaccine Effectiveness of the BNT162b2 MRNA COVID-19 Vaccine against RT-PCR Confirmed SARS-CoV-2 Infections Hospitalisations and Mortality in Prioritised Risk Groups<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> Effectiveness of the Pfizer-BioNTech vaccine &gt;7 days after the second dose ranged between 53-86% in preventing SARS-CoV-2 infection, \u226575% in preventing COVID-19 hospitalizations, and \u226589% in preventing COVID-19 deaths in a nationwide cohort study of high-risk groups in Denmark including long term care facility (LTCF) residents, individuals aged \u226565 years requiring personal care at home, individuals aged \u226585 years, healthcare workers, and individuals with comorbidities (n=864,096). Effectiveness against infection 0-7 days after the second dose ranged from 46-71%. Vaccine effectiveness against all COVID-19 related outcomes was lowest among LTCF residents.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Emborg et al.\u00a0(June 2, 2021). Vaccine Effectiveness of the BNT162b2 MRNA COVID-19 Vaccine against RT-PCR Confirmed SARS-CoV-2 Infections Hospitalisations and Mortality in Prioritised Risk Groups. Pre-print downloaded Jun 3 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.27.21257583\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.27.21257583<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10174\" class=\"su-post\">\n<h5 class=\"su-post-title\">COVID-19 Vaccination Advice via SMS-Based Video to Improve Vaccination Uncertainty in at-Risk Groups<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">An SMS\/text messaging-based intervention to address COVID-19 vaccine hesitancy using a short web-based education video delivered to a cohort of immunosuppressed patients in the UK (n=8,886, 27% response rate) was associated with an increase in the proportion of patients who reported being aware that vaccines were safe and recommended from 36% to 88% among those aged 30-49 years and from 47% to 94% among those aged 50-69 years. The authors note that a key limitation of this intervention is the absence of a comparator group.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Bateman et al.\u00a0(June 2021). COVID-19 Vaccination Advice via SMS-Based Video to Improve Vaccination Uncertainty in at-Risk Groups. The Lancet Rheumatology. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/S2665-9913(21)00148-X\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/S2665-9913(21)00148-X<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400\">Clinical Characteristics and Health Care Setting<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-10188\" class=\"su-post\">\n<h5 class=\"su-post-title\">Co-Infections, Secondary Infections, and Antimicrobial Use in Patients Hospitalised with COVID-19 during the First Pandemic Wave from the ISARIC WHO CCP-UK Study: A Multicentre, Prospective Cohort Study<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Of 1,080 microbiologically confirmed infections in patients hospitalized for COVID-19 between February and June 2020 in the UK, 762 (70.6%) were secondary, occurring &gt;2 days after hospital admission. Among patients hospitalized for COVID-19 during this period and with available data, 37% (13,390 of 36,1456) had received antimicrobials in the community prior to hospital admission, and 85% (39,258 of 46,061) received antimicrobials during inpatient care. Broad-spectrum antimicrobials including carbapenems were more frequently used than carbapenem-sparing alternatives.\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Russell et al.\u00a0(June 17, 2021). Co-Infections, Secondary Infections, and Antimicrobial Use in Patients Hospitalised with COVID-19 during the First Pandemic Wave from the ISARIC WHO CCP-UK Study: A Multicentre, Prospective Cohort Study. The Lancet Microbe. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/S2666-5247(21)00090-2\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/S2666-5247(21)00090-2<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10186\" class=\"su-post\">\n<h5 class=\"su-post-title\">Carbapenem-Resistant Klebsiella Pneumoniae Infections in ICU COVID-19 Patients\u2014A Scoping Review<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">A literature review including 10 studies found evidence of hospital-based infection caused by the bacterium <\/span><i><span style=\"font-weight: 400\">Klebsiella pneumoniae<\/span><\/i><span style=\"font-weight: 400\"> that was resistant to the carbapenem class of antibiotics among ICU patients with COVID-19 in 6 countries, ranging in prevalence from 0.35% to 53%. The majority of infected patients were male (85%), with a mean age of 61 years.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Medrzycka-Dabrowska et al.\u00a0(May 12, 2021). Carbapenem-Resistant Klebsiella Pneumoniae Infections in ICU COVID-19 Patients\u2014A Scoping Review. Journal of Clinical Medicine. <\/span><\/i><a href=\"https:\/\/doi.org\/10.3390\/jcm10102067\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.3390\/jcm10102067<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10184\" class=\"su-post\">\n<h5 class=\"su-post-title\">SARS-CoV-2 Infects Syncytiotrophoblast and Activates Inflammatory Responses in the Placenta<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> SARS-CoV-2 RNA was detected in 23 placentas (41%) from a cohort of 55 women who had SARS-CoV-2 infection during late pregnancy and had positive PCR results at delivery. Among infected placentas, three had high viral content and were obtained from mothers who presented with severe COVID-19 and had perinatal adverse outcomes. Examination of the placentas with high viral load showed efficient SARS-CoV-2 infection restricted to\u00a0 syncytiotrophoblast cells, which envelope the fetal chorionic villi and are in direct contact with maternal blood, and considerable infiltration of maternal immune cells.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Argueta et al.\u00a0(June 2, 2021). SARS-CoV-2 Infects Syncytiotrophoblast and Activates Inflammatory Responses in the Placenta. Pre-print downloaded Jun 3 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.06.01.446676\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.06.01.446676<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>Other Resources and Commentaries<\/h2>\n<ul>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/www.who.int\/news\/item\/31-05-2021-who-announces-simple-easy-to-say-labels-for-sars-cov-2-variants-of-interest-and-concern\"><span style=\"font-weight: 400\">WHO announces simple, easy-to-say labels for SARS-CoV-2 Variants of Interest and Concern<\/span><\/a><span style=\"font-weight: 400\"> (May 31)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.3390\/vaccines9060548\"><span style=\"font-weight: 400\">Factors Influencing Public Attitudes towards COVID-19 Vaccination: A Scoping Review Informed by the Socio-Ecological Model<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Vaccines (May 24)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.3390\/vaccines9050453\"><span style=\"font-weight: 400\">Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Vaccines (May 3)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1007\/s00246-021-02651-9\"><span style=\"font-weight: 400\">Multisystem Inflammatory Syndrome Associated with COVID-19 Anti-Thrombosis Guideline of Care for Children by Action<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Pediatric Cardiology (June)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1056\/NEJMc2107808\"><span style=\"font-weight: 400\">Vaccine Breakthrough Infections with SARS-CoV-2 Variants<\/span><\/a><span style=\"font-weight: 400\"> \u2013 New England Journal of Medicine (June 2)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1017\/ice.2021.262\"><span style=\"font-weight: 400\">Practices and Activities Among Healthcare Personnel with SARS-CoV-2 Infection Working in Different Healthcare Settings\u201410 Emerging Infections Program Sites, April\u2013November 2020<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Infection Control &amp; Hospital Epidemiology (June 2)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.3390\/ijerph18115693\"><span style=\"font-weight: 400\">Advocacy, Hesitancy, and Equity: Exploring U.S. Race-Related Discussions of the COVID-19 Vaccine on Twitter<\/span><\/a><span style=\"font-weight: 400\"> \u2013 International Journal of Environmental Research and Public Health (May 26)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.3390\/v13050931\"><span style=\"font-weight: 400\">A Pandemic within Other Pandemics. When a Multiple Infection of a Host Occurs: SARS-CoV-2, HIV and Mycobacterium Tuberculosis<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Viruses (May 17)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1038\/s41579-021-00573-0\"><span style=\"font-weight: 400\">SARS-CoV-2 Variants, Spike Mutations and Immune Escape<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Nature Reviews Microbiology (June 1)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.3390\/ijerph18105195\"><span style=\"font-weight: 400\">Systematic Review on Outbreaks of SARS-CoV-2 on Cruise, Navy and Cargo Ships<\/span><\/a><span style=\"font-weight: 400\"> \u2013 International Journal of Environmental Research and Public Health (May 13)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.14423\/SMJ.0000000000001254\"><span style=\"font-weight: 400\">Association of the US COVID-19 Pandemic and Attenuated Influenza Detection<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Southern Medical Journal (June)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.3390\/v13060984\"><span style=\"font-weight: 400\">Epidemic Spread of SARS-CoV-2 Lineage B.1.1.7 in Brazil<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Viruses (May 26)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.3390\/jcm10091947\"><span style=\"font-weight: 400\">Post-Acute COVID-19 Neurological Syndrome: A New Medical Challenge<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Journal of Clinical Medicine (May 1)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1177\/01410768211018951\"><span style=\"font-weight: 400\">COVID-19 Vaccine Hesitancy: The Five Cs to Tackle Behavioural and Sociodemographic Factors<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Journal of the Royal Society of Medicine (June 2)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.3390\/medicina57060523\"><span style=\"font-weight: 400\">Presence of SARS-CoV-2 and Its Entry Factors in Oral Tissues and Cells: A Systematic Review<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Medicina (May 23)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.3390\/biomedicines9050525\"><span style=\"font-weight: 400\">Mutations in the B.1.1.7 SARS-CoV-2 Spike Protein Reduce Receptor-Binding Affinity and Induce a Flexible Link to the Fusion Peptide<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Biomedicines (May)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1215\/03616878-9349100\"><span style=\"font-weight: 400\">Who Stays at Home? The Politics of Social Distancing in Brazil, Mexico, and the United States during the COVID-19 Pandemic<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Journal of Health Politics, Policy and Law (May)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.3390\/geriatrics6020048\"><span style=\"font-weight: 400\">Reducing Morbidity and Mortality Rates from COVID-19, Influenza and Pneumococcal Illness in Nursing Homes and Long-Term Care Facilities by Vaccination and Comprehensive Infection Control Interventions<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Geriatrics (May 8)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.3390\/vaccines9060557\"><span style=\"font-weight: 400\">The Relevance of Monoclonal Antibodies in the Treatment of COVID-19<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Vaccines (May)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.3390\/v13050925\"><span style=\"font-weight: 400\">An Epidemiological Analysis of SARS-CoV-2 Genomic Sequences from Different Regions of India<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Viruses (May)<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><i><span style=\"font-weight: 400\">Report prepared by the UW Alliance for Pandemic Preparedness and Global Health Security and the START Center in collaboration with and on behalf of WA DOH COVID-19 Incident Management Team<\/span><\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Preventive treatment with the monoclonal antibody bamlanivimab reduced the risk of COVID-19 among residents and staff of skilled nursing facilities who were negative for SARS-CoV-2 infection and seronegative at baseline in a randomized trial (8.5% vs 15.2%, OR=0.43 95% CI 0.28-0.68). <\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/06\/03\/sars-cov-2-infects-syncytiotrophoblast-and-activates-inflammatory-responses-in-the-placenta\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":341,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[5],"tags":[],"topic":[],"class_list":["post-10164","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19-literature-situation-report"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=10164"}],"version-history":[{"count":2,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10164\/revisions"}],"predecessor-version":[{"id":10191,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10164\/revisions\/10191"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media\/341"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=10164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=10164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=10164"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=10164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}